Eularis Updates Reports That Help Pharmaceutical Companies Do More for Real Growth Than Simply Downsizing

Author: Eularis
Dateline: London, England (LONDON, U.K.)  | Mon, 05 Apr 2010

freeNewsArticles Story Summary: “LONDON, U.K. -- The pharmaceutical industry is facing unprecedented challenges on many fronts - a slew of patient expiries, a lack of blockbusters in the pipeline to replace the patent expiries, decreasing growth in many major markets, generic competition, constantly changing regulatory and competitive environment rendering old tools for analysis obsolete, increased pressure on CEOs to deliver shareholder growth resulting in budget cuts, downsizing, and less than optimal results.”



A R T I C L E:

The pharmaceutical industry is facing unprecedented challenges on many fronts - a slew of patient expiries, a lack of blockbusters in the pipeline to replace the patent expiries, decreasing growth in many major markets, generic competition, constantly changing regulatory and competitive environment rendering old tools for analysis obsolete, increased pressure on CEOs to deliver shareholder growth resulting in budget cuts, downsizing, and less than optimal results.

Therefore, given these challenges, today is the worst time in the history of pharmaceuticals to be a pharmaceutical marketer.

Eularis has updated its reports that focus on specific key issues for pharma marketers that help them understand how to handle these specific situations. These reports uncover practices to predict how and where pharmaceutical marketing and sales investments will yield the highest market share and market share price and highlight real life case studies.

Readers will benefit from the step-by-step guidelines on successfully implementing approaches for real and measurable results available only in these reports.

Details about these updated reports can be found at:

www.ePharmaROI.com : How to Harness the Power of Social Media in Pharmaceutical eMarketing.

www.pharmaprelaunchroi.com : Pre-Launch Planning: Priming your Pharmaceutical Brand for Profit and Success.

www.GenericsDefenseStrategies.com : How to Plan an Effective Generics Defense Strategy: Planning, Tactics and Implementation.

www.PatientAdherenceROI.com : Ensuring Profitable Patient Adherence Programs: Using Analytics and Metrics to Improve the Bottom Line

www.PharmaIndustrySFE.com : Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things?

www.PharmaMarketingROI.com : Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line.

www.epharmaroi.com : How To Harness The Power Of Social Media In Pharmaceutical eMarketing.

About Eularis:

Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches, whose reliance on historical or analogue data reduces their accuracy, Eularis' proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate and optimize their sales and marketing performance.

The company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit www.eularis.com .

###


Copyright © 2010 by Eularis and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

• Web Image (72dpi): https://www.send2press.com/mediaboom/10-0405-eularis_72dpi.jpg

Story Title: Eularis Updates Reports That Help Pharmaceutical Companies Do More for Real Growth Than Simply Downsizing
• REFERENCE KEYWORDS/TERMS: Eularis, London, England, pharmaceutical analytics, Advertising and Marketing, Medical, , LONDON, U.K..

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Eularis); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Mon, 05 Apr 2010 13:58:19 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.